IN THE NEWS
Which Startup Will Make It Big Starting At Startup Connection’s Tenth Anniversary Event?
What do Life Sciences company, Immunophotonics, video game studio Butterscotch Shenanigans, and protein-packed Belgian waffle Start Right Foods have in common? Yes, they are all examples of successful St. Louis startups. Immunophotonics has raised $4.3 million in six rounds. Butterscotch Shenanigans collected $1.4 million in revenue in 2017, Start Right Foods is on the brink of distributing their product nationally. But they all found early footing by participating in Startup Connection too. Startup Connection is St. Louis’ annual showcase of early stage startups. In 2018, Startup Connection celebrates their tenth anniversary on Wednesday, November 7 from 4:30-9:00 PM at The Globe Building in downtown St. Louis.
Health Care Q&A: Synthetic blood startup’s new CEO hopes to bring product to hospitals, battlefields and eventually Mars
St. Louis Business Journal By Brian Robbins From paramedics to soldiers, a synthetic blood substitute could change the health care industry. At least that’s what KaloCyte’s new CEO Elaine Haynes believes. Haynes, who was took the position in August, brings expertise...
Washington University researcher moves closer to perfecting artificial blood
St. Louis Business Journal By Brian Robbins June 25, 2018, 6:51 am A universal blood substitute has been one of the most elusive breakthroughs for medical researchers over the past 70 years, with companies attempting to create synthetic blood that can be easily...
St. Louis synthetic blood startup raises $800,000
St. Louis Business Journal By Brian Robbins June 4, 2018, 2:41 pm A biotech startup that is developing bio-synthetic hybrid red blood cells has raised $800,000 from investors, according to a Securities and Exchange Commission filing. KaloCyte Inc., founded in 2016 and...
Wash U continues quest to develop artificial blood
By Shahla Farzan Apr 13, 2018 Thousands of people in the United States die each year due to severe blood loss, often before they reach an emergency room. To help reduce the number of trauma deaths, a Washington University research team is working to develop an...
$5 million aids development of artificial red blood cells
Research focused on preventing deaths from traumatic bleeding Washington University in St. Louis By Kristina Sauerwein February 27, 2018 Trauma is the leading cause of death for Americans under the age of 46. In the U.S., there are about 30,000 preventable deaths...
Erythromer, a nanoscale bio-synthetic artificial red cell
VJHemOnc Video Journal of Hematological Oncology Published on Dec 16, 2016 Press brief by Allan Doctor, MD of Washington University School of Medicine, St. Louis, MO, on erythromer (EM), a nanoscale bio-synthetic artificial red cell: proof of concept and In vivo...
Video: Artificial blood cells clear first phase of animal testing
SAN DIEGO | An artificial red blood cell has come close to emulating the key functions of natural cells and does not appear to be associated with the side effects such as vasospasm and poor response to changes in blood pH that hampered the development of previous...
Scientists Are Racing to Create Synthetic Blood in the Wake of Mass Tragedies | VICE.com
The Las Vegas shooting is the latest reminder that human blood isn't enough for massive, unexpected transfusions. Ankita Rao In the aftermath of the Las Vegas mass shooting on Sunday, hundreds of people lined up to give blood at a handful of donation centers in the...
Bioengineering: Doing without donors | Nature
Featured in NATURE 28 SEPTEMBER 2017 | VOL 549 | NATURE Each year, at about 13,000 collection centres worldwide, phlebotomists stick needles in the veins of healthy volunteers and amass in excess of 110 million donations of blood. The volume collected is enough to...
CONTACT US
KaloCyte, Inc.
4 N. Martin Luther King Jr. Blvd
Suite 300
Baltimore, MD 21201
QUICK LINKS
ABOUT US
KaloCyte was founded by a distinguished team of researchers in physiology, bioengineering, and trauma care and is poised to deliver ErythroMer, a dried, bio-inspired artificial red blood cell, to market. ErythroMer is envisioned for use when stored red blood cells are unavailable, undesirable or in short supply. KaloCyte is supported by over $20M in federal grants and investor funding.